ASND Earnings Date: Nov 11, 2026 (Estimated) — Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology
Updated
When is ASND's next earnings date?
Ascendis Pharma A/S (ASND) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.91 on revenue of $412.3M.
How did ASND do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Ascendis Pharma A/S posted EPS of $1.05 versus the $1.71 estimate, a miss of 34.6%. Revenue was $394.4M against a $376.8M estimate. The stock's 1-day post-earnings move was -3.6%.
How much does ASND stock move after earnings?
ASND beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.0% (up or down) in the day after earnings.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | 1.71 | 1.05 | +34.62% | $394.4M | ❌ Miss | -3.61% | +1.63% | +3.15% |
| 2026-05-07 | Q1 2026 | 0.21 | 0.32 | +52.38% | $288.8M | ✅ Beat | +4.34% | +3.26% | -10.79% |
| 2026-02-11 | Q4 2025 | -0.06 | -0.64 | -966.67% | $288.1M | ❌ Miss | -1.53% | +3.94% | +2.03% |
| 2025-11-12 | Q3 2025 | -0.41 | -1.17 | -185.12% | $249.8M | ❌ Miss | +3.63% | +6.49% | +10.64% |
| 2025-08-07 | Q2 2025 | -1.42 | -0.93 | +34.51% | $179.2M | ✅ Beat | +0.60% | +0.89% | +7.81% |
| 2025-02-12 | Q4 2024 | -1.20 | -0.68 | +43.33% | $185.6M | ✅ Beat | +12.96% | +22.55% | +21.28% |
| 2024-11-14 | Q3 2024 | -1.52 | -1.89 | -24.34% | $63.6M | ❌ Miss | +1.79% | -1.32% | +9.91% |
| 2024-09-03 | Q2 2024 | -1.56 | -2.06 | -32.05% | $38.8M | ❌ Miss | -11.27% | -14.79% | +8.62% |
Showing last 8 quarters.